Upside – $KOD +60% (pivotal Phase 3 DAYBREAK wet-AMD trial met its primary noninferiority endpoints, with most patients reaching a 24-week dosing interval) – $ARAY +39% (agrees to explore integrating Samsung NeuroLogica volumetric imaging technology with the CyberKnife platform) – $MEDS +28% (launches a GLP-1 care app offering telehealth consultations and access to branded medications) …
Read in context ›Accuray Stock (ARAY)
Track Accuray stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
ARAY
Accuray
healthcare
At close
$0.18
â–¼ -0.02 (-7.99%)
Oct 14, 4:00 PM ET
After-hours
$0.18
• +0.00 (0.00%)
Oct 14, 6:49 PM ET
Market Cap
$26.07M
P/E Ratio
—
1Y Return
-89.20%
EPS (TTM)
-$0.41
Read the latest TheStreet Pro articles mentioning Accuray, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
0 articlesNo articles mentioning ARAY yet.
Daily Diary Mentions
1 mentionUpside, Downside Movers in the Morning